Wong Evan N, Chew Avenell L, Morgan William H, Patel Praveen J, Chen Fred K
Centre for Ophthalmology and Visual Science (Lions Eye Instiute), University of Western Australia.
Department of Ophthalmology, Sir Charles Gairdner Hospital.
Asia Pac J Ophthalmol (Phila). 2017 Jan-Feb;6(1):70-79. doi: 10.22608/APO.201643.
We reviewed the current literature on the ability of microperimetry to detect non-neovascular age-related macular degeneration (AMD) disease progression. The index test was retinal sensitivity measurement assessed by microperimetry and comparators were other functional measures (best-corrected and low-luminance visual acuities, and fixation stability) and structural parameters [retinal thickness, choroidal thickness, and area of geographic atrophy (GA) determined by color fundus photographs, short-wave or near-infrared fundus autofluorescence]. The reference standard was area of GA. The literature search was conducted in January 2016 and included MEDLINE, EMBASE, the Cochrane Library, Biosis, Science Citation Index, ProQuest Health and Medicine, CINAHL, and Highwire Press. We included 6 studies that enrolled 41 eyes with intermediate AMD (from a single study) and 80 eyes with GA secondary to AMD. Retinal sensitivity measured by microperimetry was the only functional measure that consistently detected progression in each cohort. Insufficient reported data precluded meta-analysis. Various microperimetry parameters were used to assess cohort-level change in retinal sensitivity, but the methods of analysis have yet to mature in complexity in comparison with established glaucoma field progression analysis. Microperimetry-assessed retinal sensitivity measurement may be more sensitive in detecting progression than other functional measures in non-neovascular AMD. However, the lack of standardized testing protocol and methods of progression analysis hindered comparison. Harmonization of testing protocol and development of more robust methods of analyzing raw microperimetric data will facilitate clinical implementation of this valuable retinal assessment tool.
我们回顾了当前关于微视野检查检测非新生血管性年龄相关性黄斑变性(AMD)疾病进展能力的文献。指标检测为通过微视野检查评估视网膜敏感度,对照指标为其他功能测量指标(最佳矫正视力和低亮度视力以及注视稳定性)和结构参数[视网膜厚度、脉络膜厚度以及通过彩色眼底照片、短波或近红外眼底自发荧光确定的地图样萎缩(GA)面积]。参考标准为GA面积。文献检索于2016年1月进行,包括MEDLINE、EMBASE、Cochrane图书馆、Biosis、科学引文索引、ProQuest健康与医学、CINAHL以及Highwire出版社。我们纳入了6项研究,其中一项研究纳入了41只患有中度AMD的眼睛,另一项研究纳入了80只继发于AMD的GA眼睛。通过微视野检查测量的视网膜敏感度是唯一能在每个队列中持续检测到疾病进展的功能测量指标。报告的数据不足,无法进行荟萃分析。使用了各种微视野检查参数来评估队列水平的视网膜敏感度变化,但与已确立的青光眼视野进展分析相比,分析方法在复杂性上尚未成熟。在检测非新生血管性AMD的疾病进展方面,微视野检查评估的视网膜敏感度测量可能比其他功能测量指标更敏感。然而,缺乏标准化的检测方案和进展分析方法阻碍了比较。统一检测方案并开发更强大的原始微视野检查数据分析方法将有助于这种有价值的视网膜评估工具的临床应用。